Protease-Activated Receptors 2-Antagonist Suppresses Asthma by Inhibiting Reactive Oxygen Species-Thymic Stromal Lymphopoietin Inflammation and Epithelial Tight Junction Degradation
Allergy, Asthma & Immunology Research
;
: 560-571, 2019.
Article
in English
| WPRIM
| ID: wpr-762138
ABSTRACT
PURPOSE:
Protease-activated receptor 2 (PAR2) reportedly triggers the immune response in allergic asthma. We aimed to investigate the mechanism on allergic inflammation mediated by PAR2.METHODS:
Human lung epithelial cells (A549 cells) were used for in vitro, and the German cockroach extract (GCE)-induced mouse model was developed for in vivo studies.RESULTS:
In A549 cells, the levels of reactive oxygen species (ROS) and thymic stromal lymphopoietin (TSLP) were significantly increased by GCE treatment, but were suppressed by PAR2-antagonist (PAR2-ant) or N-acetylcysteine (NAC) treatment. Claudin-1 was degraded by GCE, and was restored by PAR2-ant or NAC in the cells. In the mouse model, the clinical appearance including bronchial hyperresponsiveness, bronchoalveolar lavage fluid analysis and total immunoglobulin E were significantly suppressed by PAR2-ant or NAC. Moreover, TSLP levels in the lung were suppressed by the same treatments in the lung. Claudin-1 was also degraded by GCE, and was restored by PAR2-ant or NAC.CONCLUSIONS:
ROS generation and epidermal tight junction degradation are triggered by protease, followed by the induction of TSLP in allergic asthma. Our findings could suggest that PAR2-ant or anti-oxidants could be considered for allergic diseases as preventive alternatives.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Oxygen
/
Acetylcysteine
/
Asthma
/
In Vitro Techniques
/
Immunoglobulin E
/
Immunoglobulins
/
Bronchoalveolar Lavage Fluid
/
Reactive Oxygen Species
/
Tight Junctions
/
Blattellidae
Type of study:
Prognostic study
Limits:
Animals
/
Humans
Language:
English
Journal:
Allergy, Asthma & Immunology Research
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS